Orphazyme A/S  (ORPH) 


Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Orphazyme A/S  ("Orphazyme" or "the Company") (NASDAQ: ORPH). The investigation concerns whether Orphazyme and certain of its officers and/or directors have violated federal securities laws.


On or around September 29, 2020, Orphazyme conducted its initial public offering (“IPO”), issuing 7.6 million American depositary shares (“ADSs”) priced at $11.00 per share.  Then, on May 7, 2021, Orphazyme issued a press release “announc[ing] topline data from pivotal trial of arimoclomol in Amyotrophic Lateral Sclerisos (ALS)”.  The press release disclosed that the Company’s “ORARIALS-01 pivotal trial . . . did not meet its primary and secondary endpoints to show benefit in people living with ALS.”  On this news, Orphazyme’s ADS price fell $2.81 per ADS, or 32.83%, to close at $5.75 per ADS on May 7, 2021.


If you are aware of any facts relating to this investigation, or purchased Orphazyme shares,  you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.